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Five-Year Cost of Dementia: Medicare
Abstract

About 5.5 million older adults are living with dementia, a chronic, progressive disease characterized by severe
cognitive decline. This number will likely grow significantly as the U.S. population ages, which has cost
implications for the Medicare program. A full accounting of these additional expenses will help policymakers
plan for them in their Medicare budgets. In this study, Norma Coe and colleagues examined survival and
Medicare expenditures in older adults with and without dementia to estimate dementia’s incremental costs to
Medicare in the five years after diagnosis.
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FIVE-YEAR COST OF DEMENTIA TO MEDICARE
Lindsay White, Paul Fishman, Anirban Basu, Paul K. Crane, Eric B. Larson, Norma B. Coe
Health Services Research - published online March 13, 2019

About 5.5 million older adults are living with dementia, a chronic,
progressive disease characterized by severe cognitive decline.
This number will likely grow significantly as the U.S. population
ages, which has cost implications for the Medicare program. A full
accounting of these additional expenses will help policymakers
plan for them in their Medicare budgets.
This study examined survival and Medicare expenditures in
older adults with and without dementia to estimate dementia’s
incremental costs to Medicare in the five years after diagnosis.
Patients with dementia had significantly higher expenditures in
the 12 months prior to diagnosis than patients without dementia
($17,116 vs. $10,085).

Study:
S
 ample of 4,010 older adults with dementia from longitudinal
Health & Retirement Survey
 Looked at Medicare part A and B expenditures from 19912012, 12 months before and up to 60 months after diagnosis
 Estimated 5-year costs for those with a dementia diagnosis
and for the same participants in the absence of dementia
 Accounted for changes in survival and service use
attributable to dementia

ESTIMATED 5-YEAR MEDICARE EXPENDITURES (Parts A and B)
PATIENTS WITH
DEMENTIA

$71,917

—

SAME PATIENTS WITHOUT
DEMENTIA

$56,214

—

INCREMENTAL
COST PER PATIENT

$15,704

IN THE FIVE YEARS AFTER DIAGNOSIS, INCREMENTAL
COSTS FOR PATIENTS WITH DEMENTIA WERE…
CONCENTRATED IN
YEAR 1 AFTER DIAGNOSIS
H
 alf of costs occurred in year 1
and decreased each year until the
difference in the presence and
absence of a dementia diagnosis
was nearly zero by year 5.
A
 verage costs were lower in the
last month of life for dementia
patients, due to low service use.

DRIVEN PRIMARILY BY GREATER
INTENSITY OF SERVICE USE

AFFECTED BY DIFFERENCES
IN SEX-SPECIFIC SURVIVAL

G
 reater use of Part A services
(including inpatient, skilled
nursing, and hospice care)
accounted for most of the cost.

F
 or women, survival time was
unchanged by a dementia diagnosis.
Costs were higher because of
increased use of services.

U
 se of Part B services (outpatient
care) was higher for dementia
patients in year 1, but did not differ
significantly over five years.

F
 or men, a dementia diagnosis
reduced survival. Greater use of
services was offset substantially
by decreased survival time.

IMPLICATIONS
D
 ementia’s incremental costs to Medicare are significant: the 480,000 patients newly diagnosed with Alzheimer’s in 2017 will add $3.2 billion to
Medicare spending in the next five years.
G
 iven lower costs in the last month of life, policies to reduce end-of-life costs for dementia patients may not be effective in reducing overall
Medicare expenditures.
F
 orty percent of the sample was diagnosed in an inpatient setting, leading to high costs around the time of diagnosis. Future work should examine
what role early detection could play in reducing these costs.
S
 ubsequent research should explore sociodemographic differences in dementia costs and how to reduce preventable Part A service use.
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